BEAM FY 2024 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M-83.2% YoY

Gross Profit

-$304M-478.7% margin

Operating Income

-$416M-654.3% margin

Net Income

-$377M-593.1% margin

EPS (Diluted)

$-4.58

Cash Flow

Operating Cash Flow

-$347M

Free Cash Flow

-$356M

Stock-Based Comp.

$121M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$370M

Stockholders' Equity

$734M

Cash & Equivalents

$282M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$378M	-83.2%
Gross Profit	-$304M	$378M	-180.5%
Operating Income	-$416M	-$176M	-135.5%
Net Income	-$377M	-$133M	-184.3%